Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-11-05 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于2024年限制性股票激励计划部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the completion of repurchase and cancellation of certain restricted stocks under the 2024 restricted stock incentive plan. It details the number of shares repurchased, the price, the approval process, and the impact on the company's share capital structure. The document is a formal disclosure about a share repurchase and cancellation event related to restricted stock incentives, including legal and procedural details. It does not contain financial statements or quarterly/yearly financial results, nor is it a report or presentation. It is clearly an announcement about a transaction involving the company's own shares (repurchase and cancellation). Therefore, the appropriate classification is Transaction in Own Shares (POS). The document length is under 5,000 characters, but it is not merely announcing a report publication; it is the actual announcement of a share repurchase and cancellation event.
2024-11-05 Chinese
关于收到贷款承诺函暨获得回购公司股份专项融资支持的自愿性信息披露公告
Capital/Financing Update Classification · 95% confidence The document is a voluntary disclosure announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the receipt of a loan commitment letter from the Bank of China to support the company's share repurchase plan. It details the loan amount, terms, and the regulatory compliance related to the share buyback. The document does not contain financial statements or detailed financial results but rather announces a financing update related to capital structure changes (share repurchase financing). The document length is short (1272 characters), and it is an announcement of a financing commitment, not a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP).
2024-10-31 Chinese
关于2024年第三次临时股东大会增加临时提案暨股东大会补充通知的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2024 third extraordinary general meeting of shareholders of Harbin Gloria Pharmaceuticals Co., Ltd. It includes information about the meeting date, location, agenda items (such as share repurchase proposals and election of supervisory board members), voting procedures (including cumulative voting), registration details, and proxy forms. The document is not a financial report, earnings release, or management discussion but rather a formal notice and supplementary information about a shareholders' meeting and related proposals. It does not contain financial statements or audit information. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and proposals before the vote, not the results or solicitation materials, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement about the meeting and proposals, including procedural details and proxy forms, but not the actual voting results or solicitation materials. The document length (5875 characters) and content support this classification.
2024-10-28 Chinese
关于监事辞职暨提名第六届监事会监事候选人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of company supervisors and the nomination of new candidates for the supervisory board. It includes details about the resignations, the legal compliance of the nominees, and the process for approval by the shareholders' meeting. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's supervisory board members, which falls under management or board information disclosures. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2024-10-28 Chinese
监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the supervisory board of Harbin Yuheng Pharmaceutical Co., Ltd. It discusses the approval of the company's 2024 third quarter report and the nomination of supervisory board candidates. The document is short (1256 characters) and references the actual 2024 third quarter report being disclosed elsewhere (in newspapers and on a designated website). It does not contain the financial data or the full report itself but rather announces the supervisory board's review and resolutions related to the report and board changes. Therefore, it is not the interim/quarterly report itself but an announcement related to board/management information and report approval. The document also includes information about resignations and nominations of supervisory board members, which fits the category of Board/Management Information (MANG).
2024-10-28 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of the 2024 third quarter report. It references the actual third quarter report being disclosed elsewhere (in newspapers and on a website), indicating this document itself is not the report but an announcement of the board meeting decision. The document length is short (698 characters), and it mainly serves to announce the board meeting resolution approving the quarterly report. Therefore, it fits best as a Regulatory Filing (RNS) rather than the full Interim/Quarterly Report (IR) or an Earnings Release (ER).
2024-10-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.